Administration may even be out there for digital 1×1 conferences from
About DURECT Company
DURECT is a late-stage biopharmaceutical firm pioneering the event of epigenetic therapies that concentrate on dysregulated DNA methylation to rework the remedy of significant and life-threatening situations, together with acute organ damage and most cancers. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the exercise of DNA methyltransferases (DNMTs), epigenetic enzymes which can be elevated and related to hypermethylation present in alcohol-associated hepatitis (AH) sufferers. Larsucosterol is in scientific growth for the potential remedy of AH, for which the FDA has granted Quick Observe and Breakthrough Remedy designation; metabolic dysfunction-associated steatohepatitis (MASH) can be being explored. As well as, POSIMIR ® (bupivacaine resolution) for infiltration use, a non-opioid analgesic using the revolutionary SABER ® platform expertise, is FDA-approved and is completely licensed to Innocoll Prescribed drugs on the market and distribution within the
DURECT Ahead-Wanting Statements
This press launch accommodates forward-looking statements, together with statements made pursuant to the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995, regarding: the potential to develop larsucosterol for AH, MASH or different indications, and the potential makes use of and advantages, if any, of our product candidates. Precise outcomes might differ materially from these contained within the forward-looking statements contained on this press launch, and reported outcomes shouldn’t be thought-about as a sign of future efficiency. The potential dangers and uncertainties that would trigger precise outcomes to vary from these projected embody, amongst different issues, the dangers that the Firm is unable to lift adequate capital to start the Section 3 trial of larsucosterol in AH, trial enrollment or completion takes longer than anticipated, future scientific trials of larsucosterol are delayed or don’t affirm the outcomes from subset analyses of the AHFIRM trial, together with geographic or different segmentation, or of earlier scientific or pre-clinical trials, or don’t display the protection or efficacy of larsucosterol in a statistically vital method; the danger that the FDA or different authorities companies might require extra scientific trials for larsucosterol earlier than approving larsucosterol for the remedy of AH, and that larsucosterol might by no means be accepted; and dangers associated to the sufficiency of our money sources, our anticipated capital necessities, our want or want for extra financing, our potential to proceed to satisfy the minimal bid worth for continued itemizing on Nasdaq, our potential to acquire capital to fund our operations and bills, and our potential to proceed to function as a going concern. Additional info concerning these and different dangers is included in DURECT’s most up-to-date Securities and Trade Fee (SEC) filings, together with its annual report on Type 10-Okay for the 12 months ended December 31, 2023 and quarterly report on Type 10-Q for the quarter ended June 30, 2024 beneath the heading “Risk Factors.” These experiences can be found on our web site www.durect.com beneath the “Investors” tab and on the SEC’s web site at www.sec.gov. All info supplied on this press launch and within the attachments relies on info out there to DURECT as of the date hereof, and DURECT assumes no obligation to replace this info on account of future occasions or developments, besides as required by legislation.
NOTE: POSIMIR ® is a trademark of Innocoll Prescribed drugs, Ltd. within the
